Description
Yohimbine
Yohimbine or Quebrachine, is an indole alkaloid that derives itself from the bark of two different trees found in Africa and South America. This product (do not confuse this with Yohimbe, which it comes from) is an Alpha2-Adrenergic Receptor Antagonist. It is commonly used as a veterinary drug to reverse sedation in animals. People can also use this compound to combat Erectile Dysfunction (ED), but is not as effective as other types of medication such as Viagra or Cialis. In the performance enhancing world it athletes use it with other stimulants to expedite fat loss, and has proven to be efficacious.
NOTE: There is no “miracle” fat loss drug or diet. To properly lose weight (ideally body fat, not muscle and/or water) requires a healthy diet where you remain in a calorie deficit (consuming fewer daily calories than you expend). Sufficient weekly exercise (via weight training and cardio) is also required to both build muscle and expedite fat loss. All things considered. Please note that you need to get adequate recovery and sleep (7-9 hours per night), and both are equally as important. Supplementation of essential vitamins/minerals, and the addition of thermogenic and anabolic drugs will greatly enhance fat loss. Further to this, all of these factors are equally important for optimal health, wellness, anabolism and fat loss. If you are lacking in any area, your efforts can fail. Remember that long term consistency will help you reach and sustain your goals.
Yohimbine Benefits:
- Accelerated fat loss (via lipolysis)
- Targets fat cells
- Stacks well with other stimulants
- Treatment for Erectile Dysfunction (ED)
- Possible treatment for Female Sexual Dysfunction
Terminal Half-life:
- 0.5 hrs (est)
Possible Dosage & Cycle Length:
- Men/Women @ 2.5-5 mg/pre-workout, or as needed throughout the day
- Should administer multiple times throughout the day due to the very short half-life
- If you are pregnant, DO NOT USE this compound
- Not intended for continuous daily use
Reviews
There are no reviews yet.